These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 36763081)

  • 1.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
    Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
    Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
    Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Lob SH; Akrich B; DeRyke CA; Siddiqui F; Young K; Motyl MR; Hawser SP; Sahm DF
    JAC Antimicrob Resist; 2023 Feb; 5(1):dlad003. PubMed ID: 36694850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
    Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
    J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
    Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1343-1348. PubMed ID: 38775873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
    Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and
    Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
    JAC Antimicrob Resist; 2023 Aug; 5(4):dlad098. PubMed ID: 37577157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 10. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21.
    Karlowsky JA; Wise MG; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
    JAC Antimicrob Resist; 2024 Feb; 6(1):dlad149. PubMed ID: 38161963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
    J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
    [No Abstract]   [Full Text] [Related]  

  • 14. In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):274-281. PubMed ID: 32535630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
    Delgado-Valverde M; Portillo-Calderón I; Alcalde-Rico M; Conejo MC; Hidalgo C; Del Toro Esperón C; Pascual Á
    Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):445-457. PubMed ID: 38157139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
    Karlowsky JA; Lob SH; Siddiqui F; Polis T; Vallejo JL; Young K; Motyl MR; Sahm DF
    JAC Antimicrob Resist; 2024 Jun; 6(3):dlae077. PubMed ID: 38799180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020.
    García-Fernández S; Calvo J; Cercenado E; Suárez-Barrenechea AI; Fernández-Billón M; Castillo FJ; Gálvez-Benítez L; Tubau F; Figueroa Cerón RE; Hernández-Cabezas A; González Romo F; Fariñas MC; Gómez M; Díaz-Regañón J; Cantón R
    Rev Esp Quimioter; 2023 Jun; 36(3):302-309. PubMed ID: 36951688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
    Karlowsky JA; Lob SH; Khan TK; Chen WT; Woo PCY; Seto WH; Ip M; Leung SWM; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2023 Jun; 33():260-266. PubMed ID: 37086892
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Karlowsky JA; Lob SH; DeRyke CA; Hilbert DW; Wong MT; Young K; Siddiqui F; Motyl MR; Sahm DF
    Antimicrob Agents Chemother; 2022 May; 66(5):e0018922. PubMed ID: 35491836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.